Statin inhibition of cholesterol production (WP430)

Homo sapiens

Statins inhibit endogenous cholesterol production by competitive inhibition of HMG-CoA reductase (HMGCR), the enzyme that catalyzes conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol synthesis. This pathway delineates genes involved in statin pharmacogenomics, including genes involved in mediating the effects of statins on plasma lipoprotein metabolism. Sources: [https://www.pharmgkb.org/pathway/PA2031 PharmGKB] and [http://en.wikipedia.org/wiki/Statin Wikipedia] Proteins on this pathway have targeted assays available via the [https://assays.cancer.gov/available_assays?wp_id=WP430 CPTAC Assay Portal].

Authors

Nathan Salomonis , Alex Pico , Kristina Hanspers , Thomas Kelder , Bruce Conklin , Samuel Sklar , Egon Willighagen , Martina Summer-Kutmon , Chris Evelo , Anwesha Bohler , Denise Slenter , and Eric Weitz

Activity

last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

Diseases Serious Request 2024 - MetaKids

Annotations

Disease Ontology

cardiovascular system disease

Cell Type Ontology

hepatocyte enterocyte

Pathway Ontology

statin drug pathway

Participants

Label Type Compact URI Comment
Cholesterol Metabolite cas:57-88-5
Squalene Metabolite hmdb:HMDB0000256
Acyl-CoA Metabolite chebi:17984
Phospholipid Metabolite kegg.compound:C00865
DAG Metabolite kegg.compound:C00165
VLDL Metabolite chebi:39027
Cholesterol ester Metabolite kegg.compound:C02530
Statin Metabolite chebi:35664
HMG-CoA Metabolite hmdb:HMDB0001375
IDL Metabolite chebi:132933
Lipoproteins Metabolite chebi:6495
Mevalonate Metabolite chebi:25350
HDL Metabolite chebi:47775
Fatty acid Metabolite kegg.compound:C00162
Cholic Acid Metabolite cas:81-25-4
LDL Metabolite chebi:47774
Triglyceride Metabolite kegg.compound:C00422
ABCA1 GeneProduct ncbigene:19
ABCG8 GeneProduct ncbigene:64241
APOA1 GeneProduct ncbigene:335
APOA4 GeneProduct ncbigene:337
APOC2 GeneProduct ncbigene:344
MIR33A GeneProduct ensembl:ENSG00000207932
APOC3 GeneProduct ncbigene:345
APOC1 GeneProduct ncbigene:341
APOA5 GeneProduct ncbigene:116519
CYP7A1 GeneProduct ncbigene:1581
SCARB1 GeneProduct ncbigene:949
PLTP GeneProduct ncbigene:5360
ABCG5 GeneProduct ncbigene:64240
APOA2 GeneProduct ncbigene:336
LCAT GeneProduct ncbigene:3931
LDLR GeneProduct ncbigene:3949
APOB GeneProduct ncbigene:338
DGAT1 GeneProduct ncbigene:8694
LPL GeneProduct ncbigene:4023
MIR33B GeneProduct ensembl:ENSG00000207839
SQLE GeneProduct ncbigene:6713
LIPC GeneProduct ncbigene:3990
SOAT1 GeneProduct ncbigene:6646
APOE GeneProduct ncbigene:348
LRP1 GeneProduct ncbigene:4035
FDFT1 GeneProduct ncbigene:2222
CETP GeneProduct ncbigene:1071
HMGCR GeneProduct ncbigene:3156
Acyl-CoA synthetase Protein ncbigene:84532
MTTP Protein ncbigene:4547
PDIA2 Protein ncbigene:64714

References

  1. Microsomal triglyceride transfer protein. Wetterau JR, Lin MC, Jamil H. Biochim Biophys Acta. 1997 Apr 1;1345(2):136–50. PubMed Europe PMC Scholia
  2. Direct effects of statins on cells primarily involved in atherosclerosis. Chen H, Ikeda U, Shimpo M, Shimada K. Hypertens Res. 2000 Mar;23(2):187–92. PubMed Europe PMC Scholia